Metabolic Effects of Polycystic Ovary Syndrome in Adolescents

Overview

Journal Ann Pediatr Endocrinol Metab

Specialty Pediatrics

Date 2015 Oct 30

PMID 26512349

Citations 10

Authors

Yejin Han

Hae Soon Kim

Hye-Jin Lee

Jee-Young Oh

Yeon-Ah Sung

Affiliations

Soon will be listed here.

Abstract

Purpose: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenic anovulation in women of reproductive age. We investigated the metabolic effects of lean and overweight adolescents with PCOS.

Methods: Anthropometric measurements and biochemical parameters were evaluated in 49 adolescents with PCOS and 40 age- and body mass index (BMI)-matched controls. We further divided both PCOS and control groups into those having BMI within the normal range of less than 85(th) percentile and those being overweight and obese with a BMI greater than 85(th) percentile.

Results: Hemoglobin, gamma-glutamyl transferase (r-GT), total cholesterol, low-density lipoprotein-cholesterol and 2-hour postglucose load plasma insulin levels were significantly elevated in the lean PCOS group than in the lean control group. In the overweight/obese PCOS group, hemoglobin and r-GT levels were significantly elevated than in the overweight/obese control group. In the normal weight group, none of the subjects had metabolic syndrome according to the Adult Treatment Panel III criteria, but the incidence of metabolic syndrome in the overweight/obese PCOS group was 8.3% and that in the overweight/obese control group was 6.7%.

Conclusion: PCOS in adolescents causes metabolic abnormalities, underscoring the importance of early diagnosis of PCOS in oligomenorrheic adolescents.

Citing Articles

Retinol intake and PCOS management: a plasma metabolite and protein analysis via Mendelian randomization and NHANES 2011-2016.

Chen P, Ni S, Liu Q, Ou-Yang L Front Nutr. 2024; 11:1434648.

PMID: 39507894 PMC: 11537956. DOI: 10.3389/fnut.2024.1434648.

Higher Cumulative Live Birth Rate but Also Higher Late Miscarriage Risk in Non-Obese Women with Polycystic Ovary Syndrome Undergoing the First IVF/ICSI Cycle.

Liu S, Zhou X, Jie H, Zheng Z, Cai B, Mai Q Int J Womens Health. 2024; 16:289-298.

PMID: 38415060 PMC: 10898478. DOI: 10.2147/IJWH.S445021.

Association of insulin resistance with polycystic ovary syndrome phenotypes and patients' characteristics: a cross-sectional study in Iran.

Rahmatnezhad L, Moghaddam-Banaem L, Behroozi-Lak T, Shiva A, Rasouli J Reprod Biol Endocrinol. 2023; 21(1):113.

PMID: 38001527 PMC: 10675950. DOI: 10.1186/s12958-023-01160-z.

The Association Between Polycystic Ovary Syndrome and Metabolic Syndrome in Adolescents: a Systematic Review and Meta-analysis.

Fu L, Xie N, Qu F, Zhou J, Wang F Reprod Sci. 2022; 30(1):28-40.

PMID: 35107824 PMC: 9810687. DOI: 10.1007/s43032-022-00864-8.

PCOS and nutritional approaches: Differences between lean and obese phenotype.

Barrea L, Frias-Toral E, Verde L, Ceriani F, Cucalon G, Garcia-Velasquez E Metabol Open. 2021; 12:100123.

PMID: 34622189 PMC: 8479825. DOI: 10.1016/j.metop.2021.100123.

References

Steinberger J, Moorehead C, Katch V, Rocchini A . Relationship between insulin resistance and abnormal lipid profile in obese adolescents. J Pediatr. 1995; 126(5 Pt 1):690-5. DOI: 10.1016/s0022-3476(95)70394-2. View

Park H, Choi Y, Lee H, Oh J, Hong Y, Sung Y . The metabolic syndrome in young Korean women with polycystic ovary syndrome. Diabetes Res Clin Pract. 2007; 77 Suppl 1:S243-6. DOI: 10.1016/j.diabres.2007.01.065. View

Diamanti-Kandarakis E, Papavassiliou A, Kandarakis S, Chrousos G . Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007; 18(7):280-5. DOI: 10.1016/j.tem.2007.07.004. View

Orio Jr F, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F . The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab. 2004; 89(8):3696-701. DOI: 10.1210/jc.2003-032049. View

Escobar-Morreale H, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P . Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2011; 18(2):146-70. DOI: 10.1093/humupd/dmr042. View

Berria R, Gastaldelli A, Lucidi S, Belfort R, Filippis E, Easton C . Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther. 2006; 80(2):105-14. DOI: 10.1016/j.clpt.2006.03.014. View

Legro R, Arslanian S, Ehrmann D, Hoeger K, Murad M, Pasquali R . Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013; 98(12):4565-92. PMC: 5399492. DOI: 10.1210/jc.2013-2350. View

Sozen I, Arici A . Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstet Gynecol Surv. 2000; 55(5):321-8. DOI: 10.1097/00006254-200005000-00026. View

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

10.

Silfen M, Denburg M, Manibo A, Lobo R, Jaffe R, Ferin M . Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003; 88(10):4682-8. DOI: 10.1210/jc.2003-030617. View

11.

Norman R, Masters L, Milner C, Wang J, Davies M . Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001; 16(9):1995-8. DOI: 10.1093/humrep/16.9.1995. View

12.

Pasquali R, Casimirri F . The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf). 1993; 39(1):1-16. DOI: 10.1111/j.1365-2265.1993.tb01744.x. View

13.

Lobo R, Carmina E . The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000; 132(12):989-93. DOI: 10.7326/0003-4819-132-12-200006200-00010. View

14.

. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998; 47(RR-3):1-29. View

15.

Bitzer J, Sultan C, Creatsas G, Palacios S . Gynecological care in young women: a high-risk period of life. Gynecol Endocrinol. 2014; 30(8):542-8. DOI: 10.3109/09513590.2014.917293. View

16.

Wild R, Painter P, Coulson P, Carruth K, Ranney G . Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985; 61(5):946-51. DOI: 10.1210/jcem-61-5-946. View

17.

Legro R, Kunselman A, Dodson W, Dunaif A . Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84(1):165-9. DOI: 10.1210/jcem.84.1.5393. View

18.

Nestler J, Powers L, Matt D, Steingold K, Plymate S, Rittmaster R . A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991; 72(1):83-9. DOI: 10.1210/jcem-72-1-83. View

19.

Knochenhauer E, Key T, Kahsar-Miller M, Waggoner W, Boots L, Azziz R . Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83(9):3078-82. DOI: 10.1210/jcem.83.9.5090. View

20.

Economou F, Xyrafis X, Livadas S, Androulakis I, Argyrakopoulou G, Christakou C . In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens). 2009; 8(3):199-206. DOI: 10.14310/horm.2002.1236. View